Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Ependymoma 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Bevacizumab 10Magnetic Resonance Spectroscopy 9Temozolomide 8Cyclophosphamide 8Etoposide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Cisplatin 5Radiotherapy 4Irinotecan 4Filgrastim 4Carboplatin 4Biopsy 4Erlotinib Hydrochloride 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ependymoma × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡